Androcles

(redirected from Androclus)
Also found in: Dictionary.
Related to Androclus: Androcles

Androcles

because he had once extracted a thorn from its paw, the lion refrained from attacking Androcles in the arena. [Rom. Lit.: Brewer Dictionary, 33]

Androcles

relieves lion of thorn in paw and is repaid in arena by lion’s failure to attack him. [Rom. Lit.: Noctes Atticae, Leach, 55]
References in periodicals archive ?
The technology platform was licensed from UCSD to Androclus through the UCSD technology transfer office.
Androclus signed an agreement with a large biotech for further development and commercialization of AT-001.
Androclus Therapeutics is a private clinical stage biotechnology company developing a breakthrough technology platform and novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Based on the same technology platform, Androclus is developing orally administered therapeutic peptides for the treatment of multiple sclerosis and inflammatory bowel disease, with first clinical trials for both indications expected in 2006.
Androclus is developing a new generation of therapeutics for the treatment of autoimmune diseases.
The first institutional financing is an important step in the evolution of Androclus Therapeutics and will enable Androclus to further develop its programs in multiple sclerosis and inflammatory bowel disease.
Androclus Therapeutics is a private clinical stage biotechnology company developing a breakthrough technology platform and novel therapeutics for the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and inflammatory bowel disease (IBD).
Building on the experience with AT-001 and using the same technology platform, Androclus is developing orally administered therapeutic peptides for the treatment of MS and IBD, with INDs for both indications expected within one year.
The Androclus Therapeutics Clinical Advisory Board is now composed of:
Androclus Therapeutics is a private clinical stage biotechnology company with a mission to discover and develop novel therapeutics and technologies for the treatment of diseases involving the immune system, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.
Androclus is looking for strategic partners for further development of TCC technology for both diagnostic and therapeutic applications.
The University of California has licensed to Androclus Therapeutics exclusive rights to further develop such immunomodulation therapies for RA and other indications.